Prodrug Pharmaceutical announced on August 5 that its wholly-owned subsidiary Zhejiang Projiayuan Pharmaceutical Co., Ltd. recently received the “Notice of Approval of the Marketing Application for Chemical Ingredient Application” for the active ingredient fluzelacide issued by the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.